Please assess the completion status of the following clinical trial:

Trial Title: Intravascular Ultrasound-Guided Intervention for Venous Leg Ulcers (IGuideU)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be between 18 and 85 years of age.~* Able and willing to participate and comply with the protocol, including the defined follow-up schedule, by signing an Institutional Review Board (IRB) or Ethics Committee approved informed consent form.~* Active venous leg ulcer (CEAP C6).~* Previously completed treatment for clinically significant reflux in the superficial and/or perforator venous system of the target limb at least 3 months prior to enrollment, if clinically indicated.~* Completed at least 3 months of prescribed compression therapy after any ablation.~* Palpable dorsalis pedis or posterior tibial artery (DP/PT) pulses at ipsilateral foot or ankle brachial index (ABI) ≥0.8.~* Be able to ambulate unassisted or with non-motorized assistive devices.~* Current VLU present ≤48 months.~Exclusion Criteria:~* Patient is known pregnant or breast-feeding or planning to become pregnant in the following year.~* If antiplatelet and anticoagulation therapy cannot be tolerated.~* Previous venous stent implantation involving the target limb, target lesion, or inferior vena cava.~* Previous venovenous bypass surgery involving the target limb.~* Previous endovascular recanalization of the target lesion segment.~* Known metal allergy precluding stent implantation.~* Known or suspected to have inadequate inflow to support stent patency in the target limb.~* Active cancer diagnosis.~* Known positive test for COVID-19 (Sars-CoV-2) within the last 2 weeks and actively symptomatic.~* Known or suspected venous outflow obstruction caused by tumor compression/encasement with or without thrombus.~* Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure.~* Known renal dysfunction (defined as eGFR \<30mL/min/1.73m2) that would preclude adequate contrast usage.~* Diagnosed with right heart failure/pulmonary hypertension.~* Has known clinically significant abnormal platelet count outside laboratory reference ranges.~* Has known clinically significant abnormal white blood cell count (WBC), fever, sepsis or positive blood culture.~* Organ transplant requiring immunosuppressant therapy.~* Unstable angina pectoris, or myocardial infarction within 30 days and/or hemorrhagic stroke within 3 months.~* Subjects with an active diagnosis of osteomyelitis of the ipsilateral limb.~* Previous or planned surgical or catheter-based procedure on index leg within 30 days before or 30 days after the index procedure.~* Active participation in another investigational drug or device study.~* Subject has any condition, which, in the opinion of the investigator, precludes the subject from participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Interrogation Arm (Type: OTHER): patients will first be evaluated with MPV (limited to 3 views). The prescribed course of treatment based on the MPV results will be documented and patients will then be evaluated using IVUS. A treatment plan based on IVUS results will be compared with the MPV guided treatment plan and any differences will be documented. Any patients determined to still require venous stenting based on IVUS results will be stented accordingly using IVUS to guide stent placement.
- Deferred Interrogation Arm (Type: OTHER): Deferred Interrogation Guidelines for this study are as follows:~Mandate:~• Continued compression therapy/stockings as prescribed.~Allow:~* Periodic leg elevation.~* Sclerotherapy under ulcer bed.~* Recommend mechanical debridement as needed.~* Wound biopsy if evidence of infection.~* Systemic antibiotics if patient is diagnosed with an infection, avoid prophylactic prescription.~* Pain management medication (Pentoxifylline/Trental) allowed but not recommended~* Topical antimicrobial as needed.~Prohibit:~* Negative pressure systems.~* Artificial and/or autologous skin grafting within first 3 months after randomization and within the first 3 months for subjects that crossover from deferred interrogation to the interrogation arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues